By Katherine Hamilton
Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments.
The biopharmaceutical company posted a loss of $11.4 million, or 11 cents a share, in the three months ended Dec. 31, compared with a loss of $7.8 million, or 8 cents a share, a year earlier.
Research and development expenses increased to $9.3 million from $6.5 million the year before primarily because of increased clinical development costs for two trials and a study, as well as more expenses for personnel, Trevi said.
Full-year loss in 2024 was $47.9 million, compared with $29.1 million in 2023.
The New Haven, Conn. company did not share revenue data, in keeping with previous quarters.
Earlier this month, Trevi shares climbed after it shared positive topline results from a Phase 2a trial of Haduvio, its treatment for patients with refractory chronic cough. It also shared positive results in December for a separate trial of Haduvio.
Trevi said it completed enrollment in February for the Phase 2b Coral trial in idiopathic pulmonary fibrosis patients with chronic cough, and expects topline data in the second quarter of 2025.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 18, 2025 16:17 ET (20:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。